Allena Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Allena Pharmaceuticals's estimated annual revenue is currently $6M per year.
- Allena Pharmaceuticals received $53.0M in venture funding in December 2015.
- Allena Pharmaceuticals's estimated revenue per employee is $90,224
- Allena Pharmaceuticals's total funding is $146M.
- Allena Pharmaceuticals's current valuation is $37.1M. (January 2022}
- Allena Pharmaceuticals has 67 Employees.
- Allena Pharmaceuticals grew their employee count by 10% last year.
Allena Pharmaceuticals Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Allena Pharmaceuticals?
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease. Allena's proprietary technological approach enables the design, formulation and delivery of non-absorbed and stable enzymes orally and in sufficient doses for activity in the GI tract. This approach utilizes the GI tract to degrade metabolites, such as oxalate and urate, reducing plasma and urine levels, and in turn, reducing their disease burden on the kidney over time.keywords:Biotechnology,Cleantech,Healthcare,Mobile,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
Allena Pharmaceuticals News
Allena Pharmaceuticals, Inc., a Newton, Mass.-based specialty biopharmaceutical company, completed a $25m Series B financing. The round was led by HBM Partners, with participation from existing investors Frazier Healthcare, Third Rock Ventures, Bessemer Venture Partners and new investor Pharmst ...
Allena Pharmaceuticals, Inc., a Newton, MA-based biopharmaceutical company focused on developing and commercializing innovative non-systemic oral protein therapeutics to treat metabolic and orphan diseases, completed a $53m Series C financing. The round was led by Partner Fund Management with p ...
Company Presentation March 2021 Allena Pharmaceuticals, Inc. These slides, and the accompanying presentation, contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "inten ...
Allena Pharmaceuticals drug, Reloxaliase, is in Phase 3 clinical trials for enteric hyperoxaluria (EH), a leading cause of the most common type ...
Brokerages expect Allena Pharmaceuticals Inc (NASDAQ:ALNA) to report ($0.48) earnings per share (EPS) for the current quarter, according to ...
NEWTON, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (ALNA), a late-stage, biopharmaceutical company ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Allena Pharmaceuticals Funding
|2011-11-17||$15.0M||A||Bessemer Venture Partners, Frazier Healthcare||Article|